As Speculation Mounts In Korea, Biosimilar Play Celltrion Still Seems Likely To Sell To Big Pharma

Although Celltrion has raised eyebrows by saying it would consider the best interests of Korea’s pharmaceutical industry in a potential sale, most analysts still believe a multinational will win out. Speculation has heated up after a local report singled out AstraZeneca as a potential suitor.

More from Focus On Asia

More from Scrip